This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004; 18: 484–490.
Laurenti L, Piccioni P, Piccirillo N, Sora' F, Chiusolo P, Garzia MG et al. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in 149 patients' group. Leukemia Lymphoma 2004; 45: 2063–2070.
Fegan C, Thomas H, Bailey-Wood R, Coleman S, Phillips S, Hoy T et al. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 277–281.
Guillaume T, Rubinstein DB, Symann M . Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471–1490.
Laurenti L, Sora F, Piccirillo N, Chiusolo P, Cicconi S, Rutella S et al. Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems. Transfusion 2001; 41: 783–789.
Rutella S, Rumi C, Laurenti L, Pierelli L, Sora' F, Sica S et al. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol 2000; 108: 105–115.
Laurenti L, Sica S, Sora F, Piccirillo N, Ortu La Barbera E, Chiusolo P et al. Long-term immune recovery after CD34+ immunoselected and unselected peripheral blood progenitor cell transplantation: a case–control study. Haematologica 1999; 84: 1100–1103.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laurenti, L., Piccioni, P., Tarnani, M. et al. Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. Leukemia 19, 153–154 (2005). https://doi.org/10.1038/sj.leu.2403561
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403561
This article is cited by
-
Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia
Leukemia (2007)
-
Remission of pure red cell aplasia in T-cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab
Leukemia (2005)